← Leaderboards
Sanjay Ram
Univ Of Massachusetts Med Sch Worcester
$21,500,867
Attributed
$38,867,876
Total exposure
24
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,867,876 · 24
By mechanism
R01$25,336,443 · 6
R21$2,931,833 · 7
R33$2,868,274 · 2
R44$2,027,108 · 1
U01$2,020,447 · 1
U19$1,237,700 · 1
Top collaborators
- Peter A. Rice21 shared
- Keith Wycoff16 shared
- John A Moss10 shared
- Douglas T. Golenbock5 shared
- Sunita Gulati5 shared
- Lisa Ann Lewis3 shared
- Li Li2 shared
- Jutamas Shaughnessy2 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Peter A. Rice$21,957,165
- Jutamas Shaughnessy$429,025
Others in their field
Top investigators on “Complement”
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$128,874,888
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Steve Riordan · Westat, Inc.$94,143,268
- David R. Weir · University Of Michigan At Ann Arbor$93,718,087
- Stuart L Schreiber · Harvard University (Medical School)$88,512,978
Research focus
ComplementInfectionResistanceLipooligosaccharideAntibioticsNeisseria GonorrhoeaeEctopic PregnancyIn VivoInfertilityVaginaWomanGonorrheaLeadComplement Factor HBactericideSexually Transmitted DiseasesSurfaceAttenuatedAffectImmuneIn VitroCeftriaxoneMulti-Drug ResistanceTransmission Process
Grant awards (75)
Sialic acid analogs against multidrug-resistant gonorrhea$935,587
R01 · FY2025 · AI · contact PI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract$782,815
R01 · FY2025 · AI
Bispecific antibody for topical administration to prevent gonorrhea$299,999
R43 · FY2025 · AI
Sialic acid analogs against multidrug-resistant gonorrhea$936,377
R01 · FY2024 · AI · contact PI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract$782,815
R01 · FY2024 · AI
Bispecific antibody for topical administration to prevent gonorrhea$299,999
R43 · FY2024 · AI
Development of nanobody immunotherapeutics that prevent and treat gonorrhea$208,392
R21 · FY2024 · AI · contact PI
Sialic acid analogs against multidrug-resistant gonorrhea$928,732
R01 · FY2023 · AI · contact PI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract$796,136
R01 · FY2023 · AI
A novel vaccine against multidrug-resistant gonorrhea$298,787
R01 · FY2023 · AI · contact PI
Development of nanobody immunotherapeutics that prevent and treat gonorrhea$265,676
R21 · FY2023 · AI · contact PI
Development of nucleic acid-based vaccines against gonorrhea$209,375
R21 · FY2023 · AI · contact PI
Sialic acid analogs against multidrug-resistant gonorrhea$981,731
R01 · FY2022 · AI · contact PI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract$796,136
R01 · FY2022 · AI
A novel vaccine against multidrug-resistant gonorrhea$653,148
R01 · FY2022 · AI · contact PI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$477,355
R33 · FY2022 · AI · contact PI
Development of nucleic acid-based vaccines against gonorrhea$251,250
R21 · FY2022 · AI
Gonococcal peptide vaccine candidate display using HPV virus-like particles$181,867
R21 · FY2022 · AI · contact PI
Sialic acid analogs against multidrug-resistant gonorrhea$1,316,757
R01 · FY2021 · AI · contact PI
A novel vaccine against multidrug-resistant gonorrhea$1,227,829
R01 · FY2021 · AI · contact PI
An immunotherapeutic to prevent gonorrhea$928,633
R44 · FY2021 · AI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$862,755
R01 · FY2021 · AI · contact PI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract$813,011
R01 · FY2021 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$475,901
R33 · FY2021 · AI · contact PI
Gonococcal peptide vaccine candidate display using HPV virus-like particles$241,005
R21 · FY2021 · AI · contact PI
Outer membrane vesicle vaccine against gonococcal and meningcoccal disease$209,375
R21 · FY2021 · AI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,170,759
R01 · FY2020 · AI · contact PI
A novel vaccine against multidrug-resistant gonorrhea$1,133,414
R01 · FY2020 · AI · contact PI
An immunotherapeutic to prevent gonorrhea$798,475
R44 · FY2020 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$480,773
R33 · FY2020 · AI · contact PI
Outer membrane vesicle vaccine against gonococcal and meningcoccal disease$251,250
R21 · FY2020 · AI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,118,405
R01 · FY2019 · AI · contact PI
A novel vaccine against multidrug-resistant gonorrhea$967,287
R01 · FY2019 · AI · contact PI
Immune defenses against Neisseria gonorrhoeae$629,859
R01 · FY2019 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$495,740
R61 · FY2019 · AI · contact PI
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrhea$465,374
R33 · FY2019 · AI · contact PI
An immunotherapeutic to prevent gonorrhea$300,000
R44 · FY2019 · AI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,051,980
R01 · FY2018 · AI · contact PI
Immune defenses against Neisseria gonorrhoeae$629,859
R01 · FY2018 · AI
Gonorrhea and HIV prevention with intravaginal ring drug delivery$523,283
R61 · FY2018 · AI · contact PI
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrhea$467,677
R33 · FY2018 · AI · contact PI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea$1,250,425
R01 · FY2017 · AI · contact PI
Immune defenses against Neisseria gonorrhoeae$629,859
R01 · FY2017 · AI
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrhea$501,194
R33 · FY2017 · AI · contact PI
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co$498,200
U01 · FY2017 · AI · contact PI
A novel anti-gonorrhea immunotherapeutic$242,093
R41 · FY2017 · AI
Immune defenses against Neisseria gonorrhoeae$629,859
R01 · FY2016 · AI
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co$498,599
U01 · FY2016 · AI · contact PI
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrhea$198,699
R21 · FY2016 · AI · contact PI
Immune defenses against Neisseria gonorrhoeae$629,859
R01 · FY2015 · AI
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co$498,145
U01 · FY2015 · AI · contact PI
Sialic acid analogs as novel immunotherapeutics against multidrug-resistant gonorrhea$257,606
R21 · FY2015 · AI · contact PI
Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae$251,250
R21 · FY2015 · AI · contact PI
Immunology of Infection with Neisseria gonorrhoeae$583,230
R56 · FY2014 · AI
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co$525,503
U01 · FY2014 · AI · contact PI
Complement Activation on Neisseria meningitidis$366,424
R01 · FY2014 · AI · contact PI
Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae$208,854
R21 · FY2014 · AI · contact PI
Complement Activation on Neisseria meningitidis$344,438
R01 · FY2013 · AI · contact PI
The alternative pathway of complement and properdin in Neisseria$239,111
U19 · FY2013 · AI · contact PI
Complement Activation on Neisseria meningitidis$366,424
R01 · FY2012 · AI · contact PI
The alternative pathway of complement and properdin in Neisseria$244,056
U19 · FY2012 · AI · contact PI
Complement Activation on Neisseria meningitidis$366,424
R01 · FY2011 · AI · contact PI
The alternative pathway of complement and properdin in Neisseria$250,943
U19 · FY2011 · AI · contact PI
Complement Activation on Neisseria meningitidis$369,656
R01 · FY2010 · AI · contact PI
The alternative pathway of complement and properdin in Neisseria$252,174
U19 · FY2010 · AI · contact PI
The alternative pathway of complement and properdin in Neisseria$251,416
U19 · FY2009 · AI · contact PI
Complement Activation on Neisseria meningitidis$302,304
R01 · FY2008 · AI · contact PI
ACTIVITY OF MENINGOCOCCAL VACCINE CANDIDATE GNA1870$650
P41 · FY2008 · RR · contact PI
Complement Activation on Neisseria meningitidis$308,159
R01 · FY2007 · AI · contact PI
Antipathogen Immunoadhesins$197,234
R21 · FY2007 · AI · contact PI
ACTIVITY OF MENINGOCOCCAL VACCINE CANDIDATE GNA1870$1,077
P41 · FY2007 · RR · contact PI
Complement Activation on Neisseria meningitidis$275,000
R01 · FY2006 · AI · contact PI
Complement Activation on Neisseria meningitidis$39,433
R01 · FY2006 · AI · contact PI
Complement Activation on Neisseria meningitidis$322,000
R01 · FY2005 · AI
Complement Activation on Neisseria meningitidis$322,000
R01 · FY2004 · AI